{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:50:54Z","timestamp":1791546654782,"version":"4.3.4"},"reference-count":250,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ejpb.2024.114530","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T09:56:51Z","timestamp":1728554211000},"page":"114530","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Formulation strategies, preparation methods, and devices for pulmonary delivery of biologics"],"prefix":"10.1016","volume":"204","author":[{"given":"Kai","family":"Berkenfeld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Carneiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Corzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Laffleur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharareh","family":"Salar-Behzadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Winkeljann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2522-568X","authenticated-orcid":false,"given":"Golbarg","family":"Esfahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2024.114530_b0005","unstructured":"FDA, (n.d.). https:\/\/www.fda.gov\/about-fda\/center-biologics-evaluation-and-research-cber\/what-are-biologics-questions-and-answers#:\u223c:text=Biologics can be composed of,such as cells and tissues."},{"key":"10.1016\/j.ejpb.2024.114530_b0010","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","article-title":"Peptide therapeutics: current status and future directions","volume":"20","author":"Fosgerau","year":"2015","journal-title":"Drug Discov. Today."},{"key":"10.1016\/j.ejpb.2024.114530_b0015","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrd2399","article-title":"Protein therapeutics: a summary and pharmacological classification","volume":"7","author":"Leader","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejpb.2024.114530_b0020","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrd.2018.183","article-title":"Non-invasive delivery strategies for biologics","volume":"18","author":"Anselmo","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejpb.2024.114530_b0025","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejpb.2023.05.010","article-title":"Microfluidic mixing as platform technology for production of chitosan nanoparticles loaded with different macromolecules","volume":"188","author":"Greco","year":"2023","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2024.114530_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/rr58","article-title":"The lung as a route for systemic delivery of therapeutic proteins and peptides","volume":"2","author":"Uchenna Agu","year":"2001","journal-title":"Respir. Res."},{"key":"10.1016\/j.ejpb.2024.114530_b0035","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3109\/00498258809041723","article-title":"Tissue distribution of drug-metabolizing enzymes in humans","volume":"18","author":"Pacifici","year":"1988","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejpb.2024.114530_b0040","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1124\/dmd.107.015966","article-title":"A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes","volume":"35","author":"Somers","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejpb.2024.114530_b0045","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1089\/jamp.2016.1297","article-title":"The history of therapeutic aerosols: a chronological review","volume":"30","author":"Stein","year":"2017","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.ejpb.2024.114530_b0050","unstructured":"United Nations Treaty Collection, (n.d.). https:\/\/treaties.un.org\/Pages\/ViewDetails.aspx?src=IND&mtdsg_no=XXVII-2-f&chapter=27&clang=_en."},{"key":"10.1016\/j.ejpb.2024.114530_b0055","first-page":"391","article-title":"The internal surface area of the adult human lung","volume":"112","author":"Hasleton","year":"1972","journal-title":"J. Anat."},{"key":"10.1016\/j.ejpb.2024.114530_b0060","doi-asserted-by":"crossref","first-page":"102196","DOI":"10.1016\/j.pupt.2023.102196","article-title":"Pulmonary drug delivery for acute respiratory distress syndrome","author":"Fei","year":"2023","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2024.114530_b0065","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3390\/pharmaceutics14020302","article-title":"Strategies to overcome biological barriers associated with pulmonary drug delivery","volume":"14","author":"Plaunt","year":"2022","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.ejpb.2024.114530_b0070","article-title":"Transparent 23-generation airway model for experimental investigation of aerosol flow and deposition within the human respiratory tract","volume":"156","author":"Moeller","year":"2021","journal-title":"J. Aerosol Sci."},{"key":"10.1016\/j.ejpb.2024.114530_b0075","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/13543776.2020.1741547","article-title":"Patented therapeutic drug delivery strategies for targeting pulmonary diseases","volume":"30","author":"Thakur","year":"2020","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejpb.2024.114530_b0080","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1053\/rmed.2002.1457","article-title":"Fundamentals of pulmonary drug delivery","volume":"97","author":"Groneberg","year":"2003","journal-title":"Respir. Med."},{"key":"10.1016\/j.ejpb.2024.114530_b0085","doi-asserted-by":"crossref","first-page":"122661","DOI":"10.1016\/j.ijpharm.2023.122661","article-title":"Airway mucus in pulmonary diseases: Muco-adhesive and muco-penetrating particles to overcome the airway mucus barriers","author":"Pangeni","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114530_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107169","article-title":"Cystic fibrosis and primary ciliary dyskinesia: Similarities and differences","author":"Pereira","year":"2023","journal-title":"Respir. Med."},{"key":"10.1016\/j.ejpb.2024.114530_b0095","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12951-022-01307-x","article-title":"A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases","volume":"20","author":"He","year":"2022","journal-title":"J. Nanobiotechnology."},{"key":"10.1016\/j.ejpb.2024.114530_b0100","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1080\/17425247.2020.1730807","article-title":"Innovative preclinical models for pulmonary drug delivery research","volume":"17","author":"Ehrmann","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2024.114530_b0105","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jconrel.2019.10.035","article-title":"Rational particle design to overcome pulmonary barriers for obstructive lung diseases therapy","volume":"314","author":"He","year":"2019","journal-title":"J. Control. Release."},{"key":"10.1016\/j.ejpb.2024.114530_b0110","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/2732017","article-title":"Inhaled therapy in respiratory disease: the complex interplay of pulmonary kinetic processes","volume":"2018","author":"Borghardt","year":"2018","journal-title":"Can. Respir. J."},{"key":"10.1016\/j.ejpb.2024.114530_b0115","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3390\/pharmaceutics11030113","article-title":"Strategies to enhance drug absorption via nasal and pulmonary routes","volume":"11","author":"Ghadiri","year":"2019","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.ejpb.2024.114530_b0120","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1089\/jamp.2020.29029.cd","article-title":"Deposition mechanisms","volume":"33","author":"Darquenne","year":"2020","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.ejpb.2024.114530_b0125","first-page":"283","article-title":"Next generation pharmaceutical impactor (a new impactor for pharmaceutical inhaler testing)","volume":"16","author":"Marple","year":"2003","journal-title":"Part i: Design, J. Aerosol Med."},{"key":"10.1016\/j.ejpb.2024.114530_b0130","unstructured":"X.M. Zeng, G.P. Martin, C. Marriott, Medicinal aerosols, Part. Interact. Dry Powder Formul. Inhal. New York, NY Taylor Fr. (2001) 66\u201391."},{"key":"10.1016\/j.ejpb.2024.114530_b0135","doi-asserted-by":"crossref","unstructured":"I. Gonda, Targeting by deposition, Pharm. Inhal. Aerosol Technol. New York, NY Marcel Dekker. (2003) 65\u201388.","DOI":"10.1201\/9780203912898.ch3"},{"key":"10.1016\/j.ejpb.2024.114530_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2010.12.040","article-title":"Influence of particle size on regional lung deposition\u2013what evidence is there?","volume":"406","author":"Carvalho","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114530_b0145","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.2174\/1381612822666160128145356","article-title":"Large porous hollow particles: lightweight champions of pulmonary drug delivery","volume":"22","author":"Gharse","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejpb.2024.114530_b0150","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ejps.2013.04.011","article-title":"Evaluation and modification of commercial dry powder inhalers for the aerosolization of a submicrometer excipient enhanced growth (EEG) formulation","volume":"49","author":"Son","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2024.114530_b0155","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s11671-023-03781-0","article-title":"Engineering of inhalable nano-in-microparticles for co-delivery of small molecules and miRNAs","volume":"18","author":"Motiei","year":"2023","journal-title":"Discov. Nano."},{"key":"10.1016\/j.ejpb.2024.114530_b0160","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1080\/17425247.2023.2263360","article-title":"Multifunctional systems based on nano-in-microparticles as strategies for drug delivery: advances, challenges, and future perspectives","volume":"20","author":"Carvalho","year":"2023","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2024.114530_b0165","first-page":"1189","article-title":"Inhalable nanoparticulate powders for respiratory delivery, Nanomedicine Nanotechnology","volume":"11","author":"Muralidharan","year":"2015","journal-title":"Biol. Med."},{"key":"10.1016\/j.ejpb.2024.114530_b0170","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1166\/jnn.2008.171","article-title":"Size dependent interactions of nanoparticles with lung surfactant model systems and the significant impact on surface potential","volume":"8","author":"Ku","year":"2008","journal-title":"J. Nanosci. Nanotechnol."},{"key":"10.1016\/j.ejpb.2024.114530_b0175","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1021\/sc500100b","article-title":"Increasing hydrophobicity of nanoparticles intensifies lung surfactant film inhibition and particle retention","volume":"2","author":"Valle","year":"2014","journal-title":"ACS Sustain. Chem. Eng."},{"key":"10.1016\/j.ejpb.2024.114530_b0180","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jconrel.2014.03.022","article-title":"Quantitative assessment of nanoparticle surface hydrophobicity and its influence on pulmonary biocompatibility","volume":"183","author":"Jones","year":"2014","journal-title":"J. Control. Release."},{"key":"10.1016\/j.ejpb.2024.114530_b0185","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.actbio.2021.11.034","article-title":"Physicochemical properties of nanoparticles affecting their fate and the physiological function of pulmonary surfactants","volume":"140","author":"Liu","year":"2022","journal-title":"Acta Biomater."},{"key":"10.1016\/j.ejpb.2024.114530_b0190","doi-asserted-by":"crossref","first-page":"20210402","DOI":"10.1098\/rsif.2021.0402","article-title":"Shape matters\u2014the interaction of gold nanoparticles with model lung surfactant monolayers","volume":"18","author":"Hossain","year":"2021","journal-title":"J. r. Soc. Interface."},{"key":"10.1016\/j.ejpb.2024.114530_b0195","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1039\/C8EN00521D","article-title":"The role of nanoparticle shape in translocation across the pulmonary surfactant layer revealed by molecular dynamics simulations","volume":"5","author":"Luo","year":"2018","journal-title":"Environ. Sci Nano."},{"key":"10.1016\/j.ejpb.2024.114530_b0200","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1016\/j.biomaterials.2013.01.064","article-title":"Nanoparticle diffusion in respiratory mucus from humans without lung disease","volume":"34","author":"Schuster","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2024.114530_b0205","doi-asserted-by":"crossref","first-page":"e1601556","DOI":"10.1126\/sciadv.1601556","article-title":"Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation","volume":"3","author":"Schneider","year":"2017","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejpb.2024.114530_b0210","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.addr.2008.11.002","article-title":"Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues","volume":"61","author":"Lai","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2024.114530_b0215","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jconrel.2004.10.010","article-title":"Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions","volume":"102","author":"Yamamoto","year":"2005","journal-title":"J. Control. Release."},{"key":"10.1016\/j.ejpb.2024.114530_b0220","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.colsurfb.2009.01.010","article-title":"Chitosan-coated liposomes for delivery to lungs by nebulisation","volume":"71","author":"Zaru","year":"2009","journal-title":"Colloids Surfaces B Biointerfaces."},{"key":"10.1016\/j.ejpb.2024.114530_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118578","article-title":"In vitro antibacterial activity of ciprofloxacin loaded chitosan microparticles and their effects on human lung epithelial cells","volume":"569","author":"Kucukoglu","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114530_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2019.115437","article-title":"A combinatorial study of experimental analysis and mathematical modeling: How do chitosan nanoparticles deliver therapeutics into cells?","volume":"229","author":"Dey","year":"2020","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ejpb.2024.114530_b0235","doi-asserted-by":"crossref","first-page":"2000312","DOI":"10.1002\/mabi.202000312","article-title":"Biomedical and pharmacological uses of fluorescein isothiocyanate chitosan-based nanocarriers","volume":"21","author":"Caprifico","year":"2021","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.ejpb.2024.114530_b0240","doi-asserted-by":"crossref","DOI":"10.1201\/9780429065767","article-title":"Antitumor effect of hyaluronic-acid-modified chitosan nanoparticles loaded with siRNA for targeted therapy for non-small cell lung cancer","author":"Zhang","year":"2019","journal-title":"Int. J. Nanomedicine."},{"key":"10.1016\/j.ejpb.2024.114530_b0245","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2217\/nnm-2017-0291","article-title":"Chitosan-coated nanoparticles enhanced lung pharmacokinetic profile of voriconazole upon pulmonary delivery in mice","volume":"13","author":"Paul","year":"2018","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ejpb.2024.114530_b0250","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1177\/0885328219863291","article-title":"Mucopenetrating lipoplexes modified with PEG and hyaluronic acid for CD44-targeted local siRNA delivery to the lungs","volume":"34","author":"Almeida","year":"2019","journal-title":"J. Biomater. Appl."},{"key":"10.1016\/j.ejpb.2024.114530_b0255","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jconrel.2020.03.032","article-title":"Peptides as surface coatings of nanoparticles that penetrate human cystic fibrosis sputum and uniformly distribute in vivo following pulmonary delivery","volume":"322","author":"Leal","year":"2020","journal-title":"J. Control. Release."},{"key":"10.1016\/j.ejpb.2024.114530_b0260","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1039\/D3BM02020G","article-title":"Lipid sulfoxide polymers as potential inhalable drug delivery platforms with differential albumin binding affinity","volume":"12","author":"Ediriweera","year":"2024","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.ejpb.2024.114530_b0265","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1124\/pr.58.1.8","article-title":"Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery","volume":"58","author":"Khalil","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejpb.2024.114530_b0270","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S1773-2247(10)50026-1","article-title":"Polymeric nanocarriers for drug delivery to the lung","volume":"20","author":"Lebhardt","year":"2010","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejpb.2024.114530_b0275","doi-asserted-by":"crossref","first-page":"11778","DOI":"10.1021\/nn505399e","article-title":"Critical determinants of uptake and translocation of nanoparticles by the human pulmonary alveolar epithelium","volume":"8","author":"Thorley","year":"2014","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejpb.2024.114530_b0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.addr.2011.02.006","article-title":"Pulmonary delivery of therapeutic siRNA","volume":"64","author":"Lam","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2024.114530_b0285","doi-asserted-by":"crossref","first-page":"8478","DOI":"10.1016\/j.biomaterials.2013.07.062","article-title":"Bioimaging and pulmonary applications of self-assembled Flt1 peptide\u2013hyaluronic acid conjugate nanoparticles","volume":"34","author":"Kim","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2024.114530_b0290","doi-asserted-by":"crossref","first-page":"e0223339","DOI":"10.1371\/journal.pone.0223339","article-title":"In vivo clearance of nanoparticles by transcytosis across alveolar epithelial cells","volume":"14","author":"Detampel","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2024.114530_b0295","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0939-6411(00)00084-9","article-title":"Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake?","volume":"50","author":"Jung","year":"2000","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2024.114530_b0300","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cocis.2017.06.003","article-title":"Polymer-drug conjugates as inhalable drug delivery systems: A review","volume":"31","author":"Marasini","year":"2017","journal-title":"Curr. Opin. Colloid Interface Sci."},{"key":"10.1016\/j.ejpb.2024.114530_b0305","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/pro.2684","article-title":"Advanced protein formulations","volume":"24","author":"Wang","year":"2015","journal-title":"Protein Sci."},{"key":"10.1016\/j.ejpb.2024.114530_b0310","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.biotechadv.2011.03.005","article-title":"Longer action means better drug: tuning up protein therapeutics","volume":"29","author":"Szlachcic","year":"2011","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.ejpb.2024.114530_b0315","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/jps.21504","article-title":"Effects of glycosylation on the stability of protein pharmaceuticals","volume":"98","author":"Sol\u00e1","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2024.114530_b0320","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ijpharm.2018.12.081","article-title":"Albumin fusion improves the pharmacokinetics and in vivo antitumor efficacy of canine interferon gamma","volume":"558","author":"Li","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114530_b0325","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jconrel.2020.05.036","article-title":"Development of a long acting FGF21 analogue-albumin fusion protein and its anti-diabetic effects","volume":"324","author":"Watanabe","year":"2020","journal-title":"J. Control. Release."},{"key":"10.1016\/j.ejpb.2024.114530_b0330","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.pep.2008.04.012","article-title":"Expression, purification, and characterization of recombinant human serum albumin fusion protein with two human glucagon-like peptide-1 mutants in Pichia pastoris","volume":"61","author":"Dou","year":"2008","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.ejpb.2024.114530_b0335","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1208\/s12249-015-0317-x","article-title":"Devices for dry powder drug delivery to the lung","volume":"16","author":"Berkenfeld","year":"2015","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2024.114530_b0340","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1208\/s12249-022-02455-x","article-title":"Formulation, device, and clinical factors influencing the targeted delivery of COVID-19 vaccines to the lungs","volume":"24","author":"Mossadeq","year":"2022","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2024.114530_b0345","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.addr.2014.04.004","article-title":"Technological and practical challenges of dry powder inhalers and formulations","volume":"75","author":"Hoppentocht","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2024.114530_b0350","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/jamp.2019.1556","article-title":"The confusing world of dry powder inhalers: it is all about inspiratory pressures, not inspiratory flow rates","volume":"33","author":"Clark","year":"2020","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.ejpb.2024.114530_b0355","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1517\/17425247.2015.995087","article-title":"Nebulizers for drug delivery to the lungs","volume":"12","author":"Martin","year":"2015","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2024.114530_b0360","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1517\/17425247.2015.999039","article-title":"Nebulization as a delivery method for mAbs in respiratory diseases","volume":"12","author":"Respaud","year":"2015","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2024.114530_b0365","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1089\/jamp.2018.1508","article-title":"Devices for improved delivery of nebulized pharmaceutical aerosols to the lungs","volume":"32","author":"Longest","year":"2019","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.ejpb.2024.114530_b0370","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.powtec.2019.08.109","article-title":"Quantifying the loading capacity of a carrier-based DPI formulation and its dependence on the blending process","volume":"356","author":"Benassi","year":"2019","journal-title":"Powder Technol."},{"key":"10.1016\/j.ejpb.2024.114530_b0375","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ijpharm.2018.06.016","article-title":"Effect of delayed pMDI actuation on the lung deposition of a fixed-dose combination aerosol drug","volume":"547","author":"Farkas","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114530_b0380","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.3390\/pharmaceutics14061185","article-title":"State of the art in capsule-based dry powder inhalers: deagglomeration techniques and the consequences for formulation aerosolization","volume":"14","author":"Gro\u00df","year":"2022","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.ejpb.2024.114530_b0385","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ijpharm.2018.10.034","article-title":"Impact of capsule type on aerodynamic performance of inhalation products: A case study using a formoterol-lactose binary or ternary blend","volume":"553","author":"Wauthoz","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114530_b0390","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1208\/s12248-012-9379-9","article-title":"Effect of device design on the in vitro performance and comparability for capsule-based dry powder inhalers","volume":"14","author":"Shur","year":"2012","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2024.114530_b0395","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1208\/s12249-014-0114-y","article-title":"Advances in device and formulation technologies for pulmonary drug delivery","volume":"15","author":"Chan","year":"2014","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2024.114530_b0400","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4155\/tde-2017-0102","article-title":"Mesh nebulizers have become the first choice for new nebulized pharmaceutical drug developments","volume":"9","author":"Pritchard","year":"2018","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.ejpb.2024.114530_b0405","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3390\/pharmaceutics11080406","article-title":"Aerosolization performance of jet nebulizers and biopharmaceutical aspects","volume":"11","author":"Adorni","year":"2019","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.ejpb.2024.114530_b0410","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3390\/pharmaceutics12080721","article-title":"Aerosol delivery of dornase alfa generated by jet and mesh nebulizers","volume":"12","author":"Chang","year":"2020","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.ejpb.2024.114530_b0415","doi-asserted-by":"crossref","first-page":"894","DOI":"10.4187\/respcare.04137","article-title":"Clinical controversies in aerosol therapy for infants and children","volume":"60","author":"DiBlasi","year":"2015","journal-title":"Respir. Care."},{"key":"10.1016\/j.ejpb.2024.114530_b0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaerosci.2020.105692","article-title":"High-efficiency dry powder aerosol delivery to children: Review and application of new technologies","volume":"153","author":"Bass","year":"2021","journal-title":"J. Aerosol Sci."},{"key":"10.1016\/j.ejpb.2024.114530_b0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2014.10.003","article-title":"Protein stability in pulmonary drug delivery via nebulization","volume":"93","author":"Hertel","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2024.114530_b0430","unstructured":"FDA, (n.d.). https:\/\/www.fda.gov\/combination-products\/about-combination-products\/combination-product-definition-combination-product-types (accessed October 6, 2024)."},{"key":"10.1016\/j.ejpb.2024.114530_b0435","unstructured":"USA Food and Drug Administartion, (n.d.). https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/principles-premarket-pathways-combination-products (accessed October 6, 2024)."},{"key":"10.1016\/j.ejpb.2024.114530_b0440","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1007\/s11095-022-03363-2","article-title":"Advancements in particle engineering for inhalation delivery of small molecules and biotherapeutics","volume":"39","author":"Chang","year":"2022","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2024.114530_b0445","doi-asserted-by":"crossref","first-page":"5158","DOI":"10.3390\/molecules27165158","article-title":"Dry powder inhalers for proteins using cryo-milled electrospun polyvinyl alcohol nanofiber mats","volume":"27","author":"Ito","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ejpb.2024.114530_b0450","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/8290963","article-title":"Dry powder inhalers: a focus on advancements in novel drug delivery systems","volume":"2016","author":"Mehta","year":"2016","journal-title":"J. Drug Deliv."},{"key":"10.1016\/j.ejpb.2024.114530_b0455","unstructured":"EMA, GUIDELINE ON THE PHARMACEUTICAL QUALITY OF INHALATION AND NASAL PRODUCTS, (n.d.). https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/ozurdex-epar-public-assessment-report_en.pdf (accessed April 10, 2023)."},{"key":"10.1016\/j.ejpb.2024.114530_b0460","unstructured":"FDA, (n.d.). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2006\/018869s014lbl.pdf."},{"key":"10.1016\/j.ejpb.2024.114530_b0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118482","article-title":"Microstructural characterization of carrier-based dry powder inhalation excipients: Insights and guidance","volume":"568","author":"Elsayed","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114530_b0470","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3390\/pharmaceutics12060535","article-title":"Development of an innovative, carrier-based dry powder inhalation formulation containing spray-dried meloxicam potassium to improve the in vitro and in silico aerodynamic properties","volume":"12","author":"Benke","year":"2020","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.ejpb.2024.114530_b0475","article-title":"Recent developments in lactose blend formulations for carrier-based dry powder inhalation","volume":"114527","author":"Hebbink","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2024.114530_b0480","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/17425247.2016.1224846","article-title":"Dry powder inhalation: past, present and future","volume":"14","author":"de Boer","year":"2017","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2024.114530_b0485","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1208\/s12249-014-0119-6","article-title":"An investigation into the effect of fine lactose particles on the fluidization behaviour and aerosolization performance of carrier-based dry powder inhaler formulations","volume":"15","author":"Kinnunen","year":"2014","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2024.114530_b0490","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ijpharm.2003.10.039","article-title":"Alternative sugars as potential carriers for dry powder inhalations","volume":"270","author":"Steckel","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114530_b0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2022.103759","article-title":"The influence of carrier type, physical characteristics, and blending techniques on the performance of dry powder inhalers","author":"Mahar","year":"2022","journal-title":"J. Drug Deliv Sci. Technol."},{"key":"10.1016\/j.ejpb.2024.114530_b0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118901","article-title":"Particle engineered mannitol for carrier-based inhalation\u2013A serious alternative?","volume":"577","author":"Hertel","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114530_b0505","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11095-013-1132-2","article-title":"Towards a more desirable dry powder inhaler formulation: large spray-dried mannitol microspheres outperform small microspheres","volume":"31","author":"Kaialy","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2024.114530_b0510","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.3390\/biomedicines10112707","article-title":"The optimisation of carrier selection in dry powder inhaler formulation and the role of surface energetics","volume":"10","author":"Abiona","year":"2022","journal-title":"Biomedicines."},{"key":"10.1016\/j.ejpb.2024.114530_b0515","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0378-5173(98)00300-7","article-title":"The role of fine particle lactose on the dispersion and deaggregation of salbutamol sulphate in an air stream in vitro","volume":"176","author":"Zeng","year":"1998","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114530_b0520","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1208\/s12249-012-9765-8","article-title":"Dry powder inhalers: study of the parameters influencing adhesion and dispersion of fluticasone propionate","volume":"13","author":"Le","year":"2012","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2024.114530_b0525","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0378-5173(99)00021-6","article-title":"Effects of particle size and adding sequence of fine lactose on the deposition of salbutamol sulphate from a dry powder formulation","volume":"182","author":"Zeng","year":"1999","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114530_b0530","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.2174\/1381612821666150820110046","article-title":"Surface energy determined by inverse gas chromatography as a tool to investigate particulate interactions in dry powder inhalers","volume":"21","author":"Das","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejpb.2024.114530_b0535","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ijpharm.2014.11.019","article-title":"Extrinsic lactose fines improve dry powder inhaler formulation performance of a cohesive batch of budesonide via agglomerate formation and consequential co-deposition","volume":"478","author":"Kinnunen","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114530_b0540","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1023\/A:1020464801786","article-title":"Particle interactions involved in aerosol dispersion of ternary interactive mixtures","volume":"19","author":"Louey","year":"2002","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2024.114530_b0545","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1023\/A:1011977826711","article-title":"Protein deposition from dry powder inhalers: fine particle multiplets as performance modifiers","volume":"15","author":"Lucas","year":"1998","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2024.114530_b0550","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ejpb.2007.11.019","article-title":"An investigation into the relationship between carrier-based dry powder inhalation performance and formulation cohesive\u2013adhesive force balances","volume":"69","author":"Jones","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2024.114530_b0555","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1007\/s11095-006-9012-7","article-title":"The influence of fine excipient particles on the performance of carrier-based dry powder inhalation formulations","volume":"23","author":"Jones","year":"2006","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2024.114530_b0560","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ijpharm.2016.05.057","article-title":"From single excipients to dual excipient platforms in dry powder inhaler products","volume":"514","author":"Shur","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114530_b0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106679","article-title":"The effect of mixing on the dispersibility of adhesive mixtures for inhalation. Comparison of high shear and Turbula mixers","volume":"193","author":"Thalberg","year":"2024","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2024.114530_b0570","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ijpharm.2010.04.032","article-title":"Improving aerosolization of drug powders by reducing powder intrinsic cohesion via a mechanical dry coating approach","volume":"394","author":"Zhou","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114530_b0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121457","article-title":"The future of dry powder inhaled therapy: Promising or discouraging for systemic disorders?","volume":"614","author":"Ye","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114530_b0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119592","article-title":"Performance tuning of particle engineered mannitol in dry powder inhalation formulations","volume":"586","author":"Hertel","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114530_b0585","first-page":"S-5","article-title":"Pulmonary formulations: what remains to be done?, J. Aerosol Med. Pulm","volume":"23","author":"Weers","year":"2010","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejpb.2024.114530_b0590","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.addr.2011.07.002","article-title":"Drug\u2013lactose binding aspects in adhesive mixtures: Controlling performance in dry powder inhaler formulations by altering lactose carrier surfaces","volume":"64","author":"Zhou","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2024.114530_b0595","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1002\/jps.21629","article-title":"The role of force control agents in high-dose dry powder inhaler formulations","volume":"98","author":"Begat","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2024.114530_b0600","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ijpharm.2012.08.036","article-title":"Polymer coating of carrier excipients modify aerosol performance of adhered drugs used in dry powder inhalation therapy","volume":"438","author":"Traini","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114530_b0605","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/5635010","article-title":"Imagine the superiority of dry powder inhalers from carrier engineering","volume":"2018","author":"Mehta","year":"2018","journal-title":"J. Drug Deliv."},{"key":"10.1016\/j.ejpb.2024.114530_b0610","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11095-006-9174-3","article-title":"Particle engineering for pulmonary drug delivery","volume":"24","author":"Chow","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2024.114530_b0615","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/pat.1617","article-title":"Electrospinning and cutting of ultrafine bioerodible poly (lactide-co-ethylene oxide) tri-and multiblock copolymer fibers for inhalation applications","volume":"22","author":"Thieme","year":"2011","journal-title":"Polym. Adv. Technol."},{"key":"10.1016\/j.ejpb.2024.114530_b0620","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121601","article-title":"Development of drug alone and carrier-based GLP-1 dry powder inhaler formulations","volume":"617","author":"Babenko","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114530_b0625","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1016\/j.drudis.2021.04.009","article-title":"Leucine as an excipient in spray dried powder for inhalation","volume":"26","author":"Alhajj","year":"2021","journal-title":"Drug Discov. Today."},{"key":"10.1016\/j.ejpb.2024.114530_b0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.120121","article-title":"Development of a formulation platform for a spray-dried, inhalable tuberculosis vaccine candidate","volume":"593","author":"Gomez","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114530_b0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.120027","article-title":"Characterization of excipient enhanced growth (EEG) tobramycin dry powder aerosol formulations","volume":"591","author":"Hassan","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114530_b0640","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1007\/s13346-020-00707-6","article-title":"Co-spraying of carriers (mannitol-lactose) as a method to improve aerosolization performance of salbutamol sulfate dry powder inhaler","volume":"10","author":"Ferdynand","year":"2020","journal-title":"Drug Deliv Transl. Res."},{"key":"10.1016\/j.ejpb.2024.114530_b0645","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.1002\/jps.21362","article-title":"Cospray-dried unfractionated heparin with L-leucine as a dry powder inhaler mucolytic for cystic fibrosis therapy","volume":"97","author":"Shur","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2024.114530_b0650","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.powtec.2014.06.058","article-title":"Anti-hygroscopic effect of leucine on spray-dried herbal extract powders","volume":"266","author":"Chang","year":"2014","journal-title":"Powder Technol."},{"key":"10.1016\/j.ejpb.2024.114530_b0655","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1007\/s11095-015-1838-4","article-title":"Inhalable spray-freeze-dried powder with L-leucine that delivers particles independent of inspiratory flow pattern and inhalation device","volume":"33","author":"Otake","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2024.114530_b0660","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejpb.2016.02.010","article-title":"L-Leucine as an excipient against moisture on in vitro aerosolization performances of highly hygroscopic spray-dried powders","volume":"102","author":"Li","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2024.114530_b0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2022.09.116","article-title":"Pulmonary drug delivery applications of natural polysaccharide polymer derived nano\/micro-carrier systems: A review","author":"Balde","year":"2022","journal-title":"Int. J. Biol Macromol"},{"key":"10.1016\/j.ejpb.2024.114530_b0670","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/BF02027210","article-title":"Effects of hyaluronic acid on macrophage phagocytosis and active oxygen release","volume":"38","author":"Suzuki","year":"1993","journal-title":"Agents Actions."},{"key":"10.1016\/j.ejpb.2024.114530_b0675","doi-asserted-by":"crossref","unstructured":"K.G. Rice, The Chemistry, Biology, and Medical Applications of Hyaluronan and Its Derivatives Edited by TC Laurent. Portland Press, London, UK 1998. xvi+ 341 pp. 17\u00d7 25 cm. ISBN 1-85578-119-0. $127.50., (1998).","DOI":"10.1021\/jm980609z"},{"key":"10.1016\/j.ejpb.2024.114530_b0680","unstructured":"G. Jederstr\u00f6m, Low molecular weight hyaluronic acid with peptide or protein, (2001)."},{"key":"10.1016\/j.ejpb.2024.114530_b0685","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0168-3659(03)00263-3","article-title":"Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs","volume":"91","author":"Surendrakumar","year":"2003","journal-title":"J. Control. Release."},{"key":"10.1016\/j.ejpb.2024.114530_b0690","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jconrel.2022.09.024","article-title":"Mucoadhesive carriers for oral drug delivery","volume":"351","author":"Kumar","year":"2022","journal-title":"J. Control. Release."},{"key":"10.1016\/j.ejpb.2024.114530_b0695","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1208\/s12249-016-0633-9","article-title":"Formulation and characterization of polysaccharide microparticles for pulmonary delivery of sodium cromoglycate","volume":"18","author":"Gallo","year":"2017","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2024.114530_b0700","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.immuni.2016.02.004","article-title":"The vaccine adjuvant chitosan promotes cellular immunity via DNA sensor cGAS-STING-dependent induction of type I interferons","volume":"44","author":"Carroll","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.ejpb.2024.114530_b0705","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1166\/rnn.2014.1047","article-title":"Chitosan-based nanoparticles for drug delivery","volume":"3","author":"Homayoni","year":"2014","journal-title":"Rev. Nanosci. Nanotechnol."},{"key":"10.1016\/j.ejpb.2024.114530_b0710","doi-asserted-by":"crossref","first-page":"14341","DOI":"10.1039\/C6NR03256G","article-title":"Recent advances in chitosan-based nanoparticulate pulmonary drug delivery","volume":"8","author":"Islam","year":"2016","journal-title":"Nanoscale"},{"key":"10.1016\/j.ejpb.2024.114530_b0715","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ijpharm.2013.04.009","article-title":"Spray dried inhalable ciprofloxacin powder with improved aerosolisation and antimicrobial activity","volume":"449","author":"Osman","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114530_b0720","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.carbpol.2015.11.072","article-title":"Biphasic release of gentamicin from chitosan\/fucoidan nanoparticles for pulmonary delivery","volume":"138","author":"Huang","year":"2016","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ejpb.2024.114530_b0725","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ijpharm.2013.02.035","article-title":"Systemic heparin delivery by the pulmonary route using chitosan and glycol chitosan nanoparticles","volume":"447","author":"Trapani","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114530_b0730","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ijpharm.2009.01.017","article-title":"Sustained delivery by leucine-modified chitosan spray-dried respirable powders","volume":"372","author":"Learoyd","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114530_b0735","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s11095-006-0027-x","article-title":"Chitosan-modified dry powder formulations for pulmonary gene delivery","volume":"23","author":"Li","year":"2006","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2024.114530_b0740","doi-asserted-by":"crossref","first-page":"2381340","DOI":"10.1080\/10717544.2024.2381340","article-title":"Disordered mesoporous silica particles: an emerging platform to deliver proteins to the lungs","volume":"31","author":"Roc\u00edo Hern\u00e1ndez","year":"2024","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejpb.2024.114530_b0745","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.carbpol.2016.10.041","article-title":"N, N, N-Trimethyl chitosan: An advanced polymer with myriad of opportunities in nanomedicine","volume":"157","author":"Kulkarni","year":"2017","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ejpb.2024.114530_b0750","doi-asserted-by":"crossref","DOI":"10.1021\/acs.accounts.9b00368","article-title":"Lipid nanoparticle technology for clinical translation of siRNA therapeutics","volume":"52","author":"Kulkarni","year":"2019","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ejpb.2024.114530_b0755","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ejpb.2024.114530_b0760","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120586","article-title":"mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability","volume":"601","author":"Schoenmaker","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114530_b0765","doi-asserted-by":"crossref","first-page":"4787","DOI":"10.1021\/acsnano.8b01516","article-title":"On the formation and morphology of lipid nanoparticles containing ionizable cationic lipids and siRNA","volume":"12","author":"Kulkarni","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejpb.2024.114530_b0770","article-title":"The role of lipid components in lipid nanoparticles for vaccines and gene therapy","volume":"188","author":"Albertsen","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2024.114530_b0775","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1126\/science.281.5373.78","article-title":"An inverted hexagonal phase of cationic liposome-DNA complexes related to DNA release and delivery","volume":"281","author":"Koltover","year":"1998","journal-title":"Science (80-)"},{"key":"10.1016\/j.ejpb.2024.114530_b0780","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.ejpb.2024.114530_b0785","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.xphs.2022.12.026","article-title":"Effect of cholesterol content of lipid composition in mRNA-LNPs on the protein expression in the injected site and liver after local administration in mice","volume":"112","author":"Kawaguchi","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2024.114530_b0790","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119792","article-title":"PEG shedding-rate-dependent blood clearance of PEGylated lipid nanoparticles in mice: Faster PEG shedding attenuates anti-PEG IgM production","volume":"588","author":"Suzuki","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114530_b0795","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1021\/acs.biomac.5b01480","article-title":"Pegylated polyaspartamide\u2013polylactide-based nanoparticles penetrating cystic fibrosis artificial mucus","volume":"17","author":"Craparo","year":"2016","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.ejpb.2024.114530_b0800","doi-asserted-by":"crossref","DOI":"10.1021\/acs.molpharmaceut.2c01036","article-title":"Investigating generation of antibodies against the lipid nanoparticle vector following COVID-19 vaccination with an mRNA vaccine","author":"M\u00fcnter","year":"2023","journal-title":"Mol Pharm"},{"key":"10.1016\/j.ejpb.2024.114530_b0805","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jconrel.2022.09.021","article-title":"Spray drying siRNA-lipid nanoparticles for dry powder pulmonary delivery","volume":"351","author":"Zimmermann","year":"2022","journal-title":"J. Control. Release."},{"key":"10.1016\/j.ejpb.2024.114530_b0810","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/s41551-021-00786-x","article-title":"Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs","volume":"5","author":"Lokugamage","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.ejpb.2024.114530_b0815","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10092179","article-title":"Lipid nanoparticles as delivery vehicles for inhaled therapeutics","volume":"10","author":"Leong","year":"2022","journal-title":"Biomedicines."},{"key":"10.1016\/j.ejpb.2024.114530_b0820","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1016\/j.apsb.2022.04.013","article-title":"Tailoring combinatorial lipid nanoparticles for intracellular delivery of nucleic acids, proteins, and drugs","volume":"12","author":"Li","year":"2022","journal-title":"Acta Pharm. Sin. b."},{"key":"10.1016\/j.ejpb.2024.114530_b0825","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ijpharm.2008.01.046","article-title":"Inhalable liposomal formulation for vasoactive intestinal peptide","volume":"357","author":"Hajos","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114530_b0830","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jconrel.2019.01.025","article-title":"Inhalation treatment of cystic fibrosis with lumacaftor and ivacaftor co-delivered by nanostructured lipid carriers","volume":"296","author":"Garbuzenko","year":"2019","journal-title":"J. Control. Release."},{"key":"10.1016\/j.ejpb.2024.114530_b0835","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121259","article-title":"Lipid-microparticles for pulmonary delivery of active pharmaceutical ingredients: Impact of lipid crystallization on spray-drying processability","volume":"610","author":"Corzo","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114530_b0840","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123201","article-title":"Lipid-based particle engineering via spray-drying for targeted delivery of antibiotics to the lung","volume":"642","author":"Corzo","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114530_b0845","doi-asserted-by":"crossref","DOI":"10.1016\/j.cocis.2021.101497","article-title":"Natural and bioinspired excipients for dry powder inhalation formulations","volume":"56","author":"Zillen","year":"2021","journal-title":"Curr. Opin. Colloid Interface Sci."},{"key":"10.1016\/j.ejpb.2024.114530_b0850","unstructured":"U.S.F. and D. Administration, Inactive ingredients database, FDA. Gov, https\/\/Www. Accessdata. Fda. Gov\/Scripts\/Cder\/Iig\/Index. Cfm (Accessed 12 Feb. 2019). (2017)."},{"key":"10.1016\/j.ejpb.2024.114530_b0855","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113996","article-title":"Nanomedicine to fight infectious disease","volume":"179","author":"Rubey","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2024.114530_b0860","unstructured":"Arikayce, amikacin liposome inhalation suspension., (n.d.). https:\/\/www.arikayce.com. (accessed November 12, 2023)."},{"key":"10.1016\/j.ejpb.2024.114530_b0865","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2147\/MDER.S16360","article-title":"Tobramycin administered by the TOBI\u00ae Podhaler\u00ae for persons with cystic fibrosis: a review","author":"VanDevanter","year":"2011","journal-title":"Med. Devices Evid. Res."},{"key":"10.1016\/j.ejpb.2024.114530_b0870","unstructured":"Inbrija, levodopa inhalation powder, (n.d.). https:\/\/www.inbrija.com (accessed November 12, 2023)."},{"key":"10.1016\/j.ejpb.2024.114530_b0875","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2147\/COPD.S274846","article-title":"Consistent pulmonary drug delivery with whole lung deposition using the aerosphere inhaler: a review of the evidence","author":"Usmani","year":"2021","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"10.1016\/j.ejpb.2024.114530_b0880","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2010.03.017","article-title":"Formulation strategy and use of excipients in pulmonary drug delivery","volume":"392","author":"Pilcer","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114530_b0885","doi-asserted-by":"crossref","first-page":"277","DOI":"10.4155\/tde.14.3","article-title":"The PulmoSphereTM platform for pulmonary drug delivery","volume":"5","author":"Weers","year":"2014","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.ejpb.2024.114530_b0890","unstructured":"D.A. Edwards, G. Caponetti, J.S. Hrkach, N. Lotan, J. Hanes, A.A. Ben-Jebria, R.S. Langer, Aerodynamically light particles for pulmonary drug delivery, (1999)."},{"key":"10.1016\/j.ejpb.2024.114530_b0895","unstructured":"Acorda Therapeutics. (2021) ARCUS\u00ae: Innovative Technology Platform for Inhaled Medicines., (n.d.)."},{"key":"10.1016\/j.ejpb.2024.114530_b0900","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.3390\/pharmaceutics13091528","article-title":"Optimizing spray-dried porous particles for high dose delivery with a portable dry powder inhaler","volume":"13","author":"Son","year":"2021","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.ejpb.2024.114530_b0905","doi-asserted-by":"crossref","first-page":"15015","DOI":"10.1021\/la302281n","article-title":"Cosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers","volume":"28","author":"Vehring","year":"2012","journal-title":"Langmuir"},{"key":"10.1016\/j.ejpb.2024.114530_b0910","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijpharm.2018.08.049","article-title":"Micro\/nanostructured inhalable formulation based on polysaccharides: Effect of a thermoprotectant on powder properties and protein integrity","volume":"551","author":"Al-Qadi","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114530_b0915","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijpharm.2016.03.053","article-title":"Formulation of insulin-loaded N-trimethyl chitosan microparticles with improved efficacy for inhalation by supercritical fluid assisted atomization","volume":"505","author":"Shen","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114530_b0920","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0168-3659(01)00475-8","article-title":"Enhanced pulmonary absorption following aerosol administration of mucoadhesive powder microspheres","volume":"77","author":"Sakagami","year":"2001","journal-title":"J. Control. Release."},{"key":"10.1016\/j.ejpb.2024.114530_b0925","doi-asserted-by":"crossref","first-page":"e13569","DOI":"10.1111\/jfbc.13569","article-title":"Pacific white shrimp (Litopenaeus vannamei) shell chitosan and the conjugate with epigallocatechin gallate: Antioxidative and antimicrobial activities","volume":"45","author":"Mittal","year":"2021","journal-title":"J. Food Biochem."},{"key":"10.1016\/j.ejpb.2024.114530_b0930","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1007\/s10989-021-10276-y","article-title":"Crab pentapeptide and its anti-inflammatory activity on macrophage cells","volume":"27","author":"Balde","year":"2021","journal-title":"Int. J. Pept. Res. Ther."},{"key":"10.1016\/j.ejpb.2024.114530_b0935","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3390\/molecules27020473","article-title":"Chitosan nanoparticle-based system: a new insight into the promising controlled release system for lung cancer treatment","volume":"27","author":"Yee Kuen","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ejpb.2024.114530_b0940","doi-asserted-by":"crossref","DOI":"10.1016\/j.powtec.2022.117149","article-title":"Dry powders containing chitosan-based nanocapsules for pulmonary administration: Adjustment of spray-drying process and in vitro evaluation in A549 cells","volume":"399","author":"Fern\u00e1ndez-Paz","year":"2022","journal-title":"Powder Technol."},{"key":"10.1016\/j.ejpb.2024.114530_b0945","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s12951-022-01452-3","article-title":"A novel inhalable quercetin-alginate nanogel as a promising therapy for acute lung injury","volume":"20","author":"Chen","year":"2022","journal-title":"J. Nanobiotechnology."},{"key":"10.1016\/j.ejpb.2024.114530_b0950","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfa.2019.123720","article-title":"Thermosensitive polysaccharide particles for pulmonary drug delivery","volume":"580","author":"Sato","year":"2019","journal-title":"Colloids Surfaces A Physicochem. Eng. Asp."},{"key":"10.1016\/j.ejpb.2024.114530_b0955","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ejpb.2017.05.002","article-title":"pH\/redox dual-sensitive dextran nanogels for enhanced intracellular drug delivery","volume":"117","author":"Curcio","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2024.114530_b0960","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2022.101489","article-title":"Inhalable responsive polysaccharide-based antibiotic delivery nanoparticles to overcome mucus barrier for lung infection treatment","volume":"44","author":"Ren","year":"2022","journal-title":"Nano Today"},{"key":"10.1016\/j.ejpb.2024.114530_b0965","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.addr.2013.04.016","article-title":"Crosslinked ionic polysaccharides for stimuli-sensitive drug delivery","volume":"65","author":"Alvarez-Lorenzo","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2024.114530_b0970","article-title":"Perspectives on important considerations in designing nanoparticles for oral delivery applications in food","volume":"2","author":"Luo","year":"2020","journal-title":"J. Agric. Food Res."},{"key":"10.1016\/j.ejpb.2024.114530_b0975","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.carbpol.2010.06.029","article-title":"Preparation, characterization and evaluation of selenite-loaded chitosan\/TPP nanoparticles with or without zein coating","volume":"82","author":"Luo","year":"2010","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ejpb.2024.114530_b0980","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1021\/bm901428y","article-title":"Starch nanoparticles: a review","volume":"11","author":"Le Corre","year":"2010","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.ejpb.2024.114530_b0985","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.mattod.2013.06.004","article-title":"Nanocellulose: a new ageless bionanomaterial","volume":"16","author":"Dufresne","year":"2013","journal-title":"Mater. Today."},{"key":"10.1016\/j.ejpb.2024.114530_b0990","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1080\/87559129.2021.1950176","article-title":"Chitosan, chitooligosaccharides and their polyphenol conjugates: preparation, bioactivities, functionalities and applications in food systems","volume":"39","author":"Singh","year":"2023","journal-title":"Food Rev. Int."},{"key":"10.1016\/j.ejpb.2024.114530_b0995","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ijpharm.2013.07.034","article-title":"Chitosan nanoparticles: Preparation, size evolution and stability","volume":"455","author":"Rampino","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114530_b1000","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.3390\/ma15196521","article-title":"Chitosan nanoparticles: a versatile platform for biomedical applications","volume":"15","author":"Bashir","year":"2022","journal-title":"Materials (basel)"},{"key":"10.1016\/j.ejpb.2024.114530_b1005","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3390\/pharmaceutics10040267","article-title":"The microfluidic technique and the manufacturing of polysaccharide nanoparticles","volume":"10","author":"Chiesa","year":"2018","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.ejpb.2024.114530_b1010","doi-asserted-by":"crossref","DOI":"10.1021\/acsabm.1c00349","article-title":"New frontiers in pest control: chitosan nanoparticles-shielded dsRNA as an effective topical RNAi spray for gram podborer biocontrol","volume":"4","author":"Kolge","year":"2021","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.ejpb.2024.114530_b1015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2006.07.021","article-title":"Development and characterisation of chitosan nanoparticles for siRNA delivery","volume":"115","author":"Katas","year":"2006","journal-title":"J. Control. Release."},{"key":"10.1016\/j.ejpb.2024.114530_b1020","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ijbiomac.2019.06.062","article-title":"Chitosan nanoparticles: Polyphosphates cross-linking and protein delivery properties","volume":"136","author":"Abdelgawad","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejpb.2024.114530_b1025","author":"Kjems","year":"2011","journal-title":"Dehydrated Chitosan Nanoparticles"},{"key":"10.1016\/j.ejpb.2024.114530_b1030","unstructured":"S. Santra, Chitosan-based nanoparticles and methods for making and using the same, (2011)."},{"key":"10.1016\/j.ejpb.2024.114530_b1035","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jconrel.2012.06.005","article-title":"An inhalable \u03b22-adrenoceptor ligand-directed guanidinylated chitosan carrier for targeted delivery of siRNA to lung","volume":"162","author":"Luo","year":"2012","journal-title":"J. Control. Release."},{"key":"10.1016\/j.ejpb.2024.114530_b1040","article-title":"Conversion of liquid chitosan-based nanoemulsions into inhalable solid microparticles: Process challenges with polysaccharide","volume":"126991","author":"Shah","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejpb.2024.114530_b1045","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.3390\/polym12122878","article-title":"An overview of current knowledge on the properties, synthesis and applications of quaternary chitosan derivatives","volume":"12","author":"Freitas","year":"2020","journal-title":"Polymers (basel)."},{"key":"10.1016\/j.ejpb.2024.114530_b1050","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ejpb.2008.06.002","article-title":"Physicochemical properties and biocompatibility of N-trimethyl chitosan: effect of quaternization and dimethylation","volume":"70","author":"Jintapattanakit","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2024.114530_b1055","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1211\/jpp.60.9.0001","article-title":"Potential prospects of chitosan derivative trimethyl chitosan chloride (TMC) as a polymeric absorption enhancer: synthesis, characterization and applications","volume":"60","author":"Sahni","year":"2008","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2024.114530_b1060","doi-asserted-by":"crossref","DOI":"10.4172\/2332-0877.1000291","article-title":"N, N, N-trimethyl chitosan and its potential bactericidal activity: current aspects and technological applications","author":"Facchi","year":"2016","journal-title":"J. Infect. Dis Ther"},{"key":"10.1016\/j.ejpb.2024.114530_b1065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.124235","article-title":"N, N, N-Trimethyl chitosan as a permeation enhancer for inhalation drug delivery: interaction with a model pulmonary surfactant","volume":"239","author":"Szabov\u00e1","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejpb.2024.114530_b1070","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioadv.2023.213430","article-title":"Development and characterization of lung surfactant-coated polymer nanoparticles for pulmonary drug delivery","volume":"150","author":"Gonsalves","year":"2023","journal-title":"Biomater. Adv."},{"key":"10.1016\/j.ejpb.2024.114530_b1075","doi-asserted-by":"crossref","first-page":"2308775","DOI":"10.1002\/smll.202308775","article-title":"Pulmonary siRNA delivery with sophisticated amphiphilic poly (Spermine Acrylamides) for the treatment of lung fibrosis","volume":"20","author":"Adams","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.ejpb.2024.114530_b1080","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejpb.2020.04.027","article-title":"Novel approach for overcoming the stability challenges of lipid-based excipients. Part 3: Application of polyglycerol esters of fatty acids for the next generation of solid lipid nanoparticles","volume":"152","author":"Corzo","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2024.114530_b1085","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.ijpharm.2015.10.019","article-title":"Minimal amounts of dipalmitoylphosphatidylcholine improve aerosol performance of spray-dried temocillin powders for inhalation","volume":"495","author":"Cuvelier","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114530_b1090","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejpb.2013.02.020","article-title":"Towards the bioequivalence of pressurised metered dose inhalers 2. Aerodynamically equivalent particles (with and without glycerol) exhibit different biopharmaceutical profiles in vitro","volume":"86","author":"Haghi","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2024.114530_b1095","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1007\/s11095-011-0443-4","article-title":"Insulin lung deposition and clearance following Technosphere\u00ae insulin inhalation powder administration","volume":"28","author":"Cassidy","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2024.114530_b1100","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s11095-006-9789-4","article-title":"Formulation and characterization of lipid-coated tobramycin particles for dry powder inhalation","volume":"23","author":"Pilcer","year":"2006","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2024.114530_b1105","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.xphs.2021.09.004","article-title":"Effect of lipidic excipients on the particle properties and aerosol performance of high drug load spray dried particles for inhalation","volume":"111","author":"Shetty","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2024.114530_b1110","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1046\/j.1365-2125.2003.01892.x","article-title":"Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications","volume":"56","author":"Labiris","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2024.114530_b1115","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1177\/1932296814555820","article-title":"Afrezza inhaled insulin: the fastest-acting FDA-approved insulin on the market has favorable properties","volume":"8","author":"Klonoff","year":"2014","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.ejpb.2024.114530_b1120","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1146\/annurev-chembioeng-091720-034106","article-title":"Engineering advances in spray drying for pharmaceuticals","volume":"12","author":"Baumann","year":"2021","journal-title":"Annu. Rev. Chem. Biomol. Eng."},{"key":"10.1016\/j.ejpb.2024.114530_b1125","doi-asserted-by":"crossref","first-page":"7435","DOI":"10.1039\/C6SM01314G","article-title":"Control of particle morphology in the spray drying of colloidal suspensions","volume":"12","author":"Lintingre","year":"2016","journal-title":"Soft Matter"},{"key":"10.1016\/j.ejpb.2024.114530_b1130","series-title":"Microencapsul. Food Ind.","first-page":"59","article-title":"Atomization and spray drying processes","author":"Szczap","year":"2023"},{"key":"10.1016\/j.ejpb.2024.114530_b1135","first-page":"329","article-title":"Advances in spray drying technology for nanoparticle formation, Handb Nanoparticles [Internet]","author":"Wong","year":"2016","journal-title":"Cham Springer Int. Publ."},{"key":"10.1016\/j.ejpb.2024.114530_b1140","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/jps.21886","article-title":"Spray drying technique. I: Hardware and process parameters","volume":"99","author":"Cal","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2024.114530_b1145","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3390\/pharmaceutics12070625","article-title":"Unraveling particle formation: From single droplet drying to spray drying and electrospraying","volume":"12","author":"Boel","year":"2020","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.ejpb.2024.114530_b1150","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.cis.2015.05.003","article-title":"Advantages and challenges of the spray-drying technology for the production of pure drug particles and drug-loaded polymeric carriers","volume":"223","author":"Sosnik","year":"2015","journal-title":"Adv. Colloid Interface Sci."},{"key":"10.1016\/j.ejpb.2024.114530_b1155","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ejps.2018.10.026","article-title":"Spray drying of pharmaceuticals and biopharmaceuticals: Critical parameters and experimental process optimization approaches","volume":"127","author":"Ziaee","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2024.114530_b1160","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3390\/pr9040639","article-title":"Recent advances in fluidized bed hydrodynamics and transport phenomena\u2014progress and understanding","volume":"9","author":"Di Renzo","year":"2021","journal-title":"Processes."},{"key":"10.1016\/j.ejpb.2024.114530_b1165","doi-asserted-by":"crossref","first-page":"16218","DOI":"10.1038\/s41598-019-52596-6","article-title":"Analysis and classification of droplet characteristics from atomizers using multifractal analysis","volume":"9","author":"Godavarthi","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejpb.2024.114530_b1170","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1208\/s12249-021-02043-5","article-title":"Spray-dried inhalable powder formulations of therapeutic proteins and peptides","volume":"22","author":"Eedara","year":"2021","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2024.114530_b1175","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jconrel.2023.04.029","article-title":"Neutralisation of SARS-CoV-2 by monoclonal antibody through dual targeting powder formulation","volume":"358","author":"Seow","year":"2023","journal-title":"J. Control. Release."},{"key":"10.1016\/j.ejpb.2024.114530_b1180","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.xphs.2021.08.022","article-title":"Identification of stability constraints in the particle engineering of an inhaled monoclonal antibody dried powder","volume":"111","author":"Brunaugh","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2024.114530_b1185","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1208\/s12249-021-02095-7","article-title":"Local treatment of non-small cell lung cancer with a spray-dried bevacizumab formulation","volume":"22","author":"Shepard","year":"2021","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2024.114530_b1195","doi-asserted-by":"crossref","first-page":"2100073","DOI":"10.1002\/adtp.202100073","article-title":"Impact of crystalline and amorphous matrices on successful spray drying of siRNA polyplexes for inhalation of nano-in-microparticles","volume":"4","author":"Keil","year":"2021","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ejpb.2024.114530_b1200","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jconrel.2023.09.031","article-title":"Spray dried lipid nanoparticle formulations enable intratracheal delivery of mRNA","volume":"363","author":"Friis","year":"2023","journal-title":"J. Control. Release."},{"key":"10.1016\/j.ejpb.2024.114530_b1205","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ejpb.2023.11.007","article-title":"Evaluation of the effects of storage conditions on spray-dried siRNA-LNPs before and after subsequent drying","volume":"193","author":"Zimmermann","year":"2023","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2024.114530_b1210","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ijpharm.2015.04.053","article-title":"Pharmaceutical spray freeze drying","volume":"488","author":"Wanning","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114530_b1215","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s43094-023-00551-8","article-title":"Process development and quality attributes for the freeze-drying process in pharmaceuticals, biopharmaceuticals and nanomedicine delivery: a state-of-the-art review","volume":"9","author":"Pardeshi","year":"2023","journal-title":"Futur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2024.114530_b1220","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/10837450.2021.2021941","article-title":"Spray freeze-drying for inhalation application: process and formulation variables","volume":"27","author":"Rostamnezhad","year":"2022","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejpb.2024.114530_b1225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121637","article-title":"Dry powders for inhalation containing monoclonal antibodies made by thin-film freeze-drying","volume":"618","author":"Hufnagel","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114530_b1230","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121825","article-title":"Development of (Inhalable) dry powder formulations of AS01B-containing vaccines using thin-film freeze-drying","volume":"622","author":"AboulFotouh","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114530_b1235","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119564","article-title":"Impact of excipient choice on the aerodynamic performance of inhalable spray-freeze-dried powders","volume":"586","author":"Wanning","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114530_b1240","doi-asserted-by":"crossref","DOI":"10.1208\/s12249-016-0648-2","article-title":"Aerodynamic droplet stream expansion for the production of spray freeze-dried powders","volume":"18","author":"Wanning","year":"2017","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2024.114530_b1245","doi-asserted-by":"crossref","DOI":"10.1007\/s11095-022-03442-4","article-title":"Spray freeze drying of biologics: a review and applications for inhalation delivery","volume":"40","author":"Farinha","year":"2023","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2024.114530_b1250","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3109\/10520298309066811","article-title":"A new method using hexamethyldisilazane for preparation of soft insect tissues for scanning electron microscopy","volume":"58","author":"Nation","year":"1983","journal-title":"Stain Technol."},{"key":"10.1016\/j.ejpb.2024.114530_b1255","doi-asserted-by":"crossref","DOI":"10.1016\/S0091-679X(08)00409-3","article-title":"Chapter 9 close-to-native ultrastructural preservation by high pressure freezing","volume":"88","author":"Vanhecke","year":"2008","journal-title":"Methods Cell Biol."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641124003564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641124003564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T19:10:02Z","timestamp":1729710602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641124003564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":250,"alternative-id":["S0939641124003564"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2024.114530","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Formulation strategies, preparation methods, and devices for pulmonary delivery of biologics","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2024.114530","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114530"}}